Introduction {#Sec1}
============

Oropharyngeal squamous cell carcinoma (OSCC) accounts for over 1300 new cancer diagnoses in Canada each year \[[@CR1]\]. OSCC has traditionally been associated with alcohol and tobacco use, accounting for up to 75% of cases \[[@CR2]\], but public health initiatives have resulted in an overall decline in head and neck cancers. Despite this, rates of OSCC have continued to rise \[[@CR3], [@CR4]\]. This trend is due to a growing proportion of cases associated with infection by the human papillomavirus (HPV) \[[@CR4]\]. In Canada, the proportion of HPV associated cases has risen to approximately 75% \[[@CR5]\]. Immunohistochemistry for the expression of p16 has been correlated to the presence of HPV associated disease, and therefore p16 positivity was considered to be HPV association in this study.

HPV-associated OSCC (p16 + OSCC) appears to be a unique disease entity from non-HPV associated OSCC. p16 + OSCC is associated with a more favourable prognosis in general, with improved rates of locoregional control and survival, compared to non HPV-associated OSCC (p16-OSCC) \[[@CR6]\]. Current management approaches in patients diagnosed with HPV-OSCC often employ multimodality treatment including combinations of surgery, radiotherapy, and chemotherapy. Unfortunately, these treatments are associated with significant long-term toxicity, including organ sacrifice, severe dysphagia, and speech impairment \[[@CR7]\].

The combination of superior cancer outcomes in the p16 + OSCC patient population as well as its younger age at the time of diagnosis \[[@CR8]\] means that more head and neck cancer patients are now living with chronic toxicities from treatment. This has prompted interest in the possibility of treatment de-escalation for appropriate patients in an effort to improve toxicities without compromising cancer outcomes.

Ongoing clinical trials examining a variety of de-intensification approaches suggest that low-risk patients may have progression free survival and overall survival above 95% \[[@CR9]\].

In order for p16 + OSCC patients to benefit from treatment deintensification, treatment must be guided by accurate prognostic models. Recently, several key factors affecting patient prognosis have been identified \[[@CR10]\] and putative risk stratification models have been developed \[[@CR10]--[@CR13]\]. Smoking, lymph node involvement, age, and patient comorbidities play an integral role in this determination, as anatomic staging alone has been deemed insufficient for prognostic purposes in p16 + OSCC \[[@CR14]\]. The American Joint Committee on Cancer (AJCC) has therefore significantly altered its staging system for oropharyngeal cancers, creating a separate staging system for HPV-associated disease in its most recent edition \[[@CR15]\].

Little is known about the p16 + OSCC population in Nova Scotia, and information regarding risk distribution in these patients is similarly lacking. Nova Scotia has a high prevalence of smoking, behind only the Territories as the province with the highest smoking rates in Canada \[[@CR16]\]. This study aimed to quantify patient risk distribution using multiple published risk models and investigate the hypothesis that the local p16 + OSCC population includes a smaller proportion of low-risk patients due to a high prevalence of concurrent tobacco exposure. Through this objective, we also aimed to answer important questions regarding our local patient population, including the average age, sex distribution, and smoking rate of p16 + OSCC patients. This is the first study to directly compare a local study population to multiple putative risk stratification models, and the first study to identify the risk distribution in Nova Scotia.

Methods {#Sec2}
=======

Study design {#Sec3}
------------

This study was a retrospective cohort analysis of patients diagnosed with oropharyngeal squamous cell carcinoma between 2011 and 2015, inclusive. Patient data was obtained through the Cancer Care Nova Scotia patient registry and an institutional transoral laser microsurgery database. Electronic patient charts were subsequently reviewed for completeness. Patients were considered to have HPV-associated disease when they displayed p16 positivity on immunohistochemistry, defined as greater than 70% staining. Variables examined included gender, age, tumor-node-metastasis (TNM) staging, subsite of primary tumor, smoking history, and comorbidities at time of diagnosis. When available, pathological staging was used. When unavailable, clinical staging was utilized. American Joint Committee on Cancer Seventh Edition was utilized for TNM staging purposes during this study. Notably, following completion of data gathering in this study, the AJCC eighth edition has been released and adopted by our institution.

Smoking history and comorbidities were obtained from consultation notes, clinic follow-up notes, anesthesia assessments, and clinic nursing assessments. Patients were considered to have a positive smoking history when pack-year was greater than one. This is similar to Ang et al. which divided patients into never smoked, former smoker, and current smoker categories. Subsite of the primary tumor was determined by a physical examination performed by the treating head and neck surgeon, radiation oncologist, or medical oncologist.

Exclusion criteria included incomplete data availability, local recurrence cases, and second primary cases.

Ethics approval {#Sec4}
---------------

Ethics approval was granted by the Nova Scotia Health Authority Research Ethics Board.

Models and analysis {#Sec5}
-------------------

Patients were stratified using previously reported stratification algorithms \[[@CR10]--[@CR13]\]. O'Sullivan and colleagues proposed a model using only HPV status, and tumor and nodal staging. Patients were stratified into non-HPV-OSCC and HPV-OSCC low and high risk in the original study. For the purposes of this study, the original stratifications were recalculated for p16 + OSCC only. Dahlstrom and colleagues likewise used tumor and nodal staging. The intermediate group was combined for calculation purposes. Ang and colleagues utilized HPV status, smoking status, and nodal status. Similar to O'Sullivan and colleagues, stratification was recalculated to include only p16 + OSCC. Finally, Huang et al. combined age, tumor and nodal staging, and smoking history to create four risk groups. The two intermediate groups were combined into a single intermediate group for this study.

Statistics were descriptive in nature and completed using SPSS Statistics (SPSS®, IBM®, version 21).

Results {#Sec6}
=======

Patient demographics {#Sec7}
--------------------

In total, 142 p16 positive patients were identified. Nine patients were excluded due to incomplete access to electronic medical records, and sixteen were excluded due to incomplete smoking status data. Therefore, 117 patients were included in the analysis.

The majority of patients were male (Table [1](#Tab1){ref-type="table"}, 87.2%). The mean age at time of diagnosis was 58.1 years (Table [1](#Tab1){ref-type="table"}, range 33--83). The majority of patients had T2 primary tumors or smaller on presentation (Table [1](#Tab1){ref-type="table"}, 70.9%). The majority of patients had advanced nodal status on presentation, with 60.7% of patients presenting with N2b or greater. Of these patients, the greatest proportion was N2b, representing 41.9% of patients (Table [1](#Tab1){ref-type="table"}).Table 1Patient demographics and TNM StagingVariableNumber of Patients (%) or mean (range)Male Gender102 (87.2)Age58.1 (33--83)Age \> 706 (5.1)Positive Smoking History73 (62.4)Pack-Year History28.8 (2--150)Continued Smoking27 (23.1)Cessation ≥10 y26 (22.2)Primary Tumor Subsite Base of Tongue36 (30.8) Tonsil79 (67.5) Vallecula1 (0.9) Soft Palate1 (0.9)Tumor Stage (T) T131 (26.5) T252 (44.4) T321 (17.9) T412 (11.2)Nodal Stage (N) N011 (9.4) N113 (11.1) N2a22(18.8) N2b49 (41.9) N2c19 (16.2) N33 (2.6)Metastasis Stage (M) M0117 (100) M10 (0)

More than half of the patients had a positive smoking history (Table [1](#Tab1){ref-type="table"}, 62.4%). Of the patients with a positive smoking history, the mean pack-year history was 28.8 pack-years (Table [1](#Tab1){ref-type="table"}, range 2--150). Sixty-two patients had a pack-year history greater than 10 pack-years (53.0%), and 38 patients had a pack-year history greater than 20 pack-years (32.5%). Stratifying by gender showed 40% of females had a positive smoking history, with a mean pack-year history of 39.7 pack-years. Amongst men, both the prevalence tobacco exposure (37.3%) and mean pack-year history (27.3 pack-years) were lower.

Risk stratification {#Sec8}
-------------------

Risk stratification using the model proposed by Ang et al. \[[@CR10]\] revealed 66.7% of patients were low risk (Table [2](#Tab2){ref-type="table"}). Age and pack-year history greater than 20 were combined with TNM staging by Huang and colleagues \[[@CR12]\], and revealed no patients in the highest risk category in the local study population (Table [2](#Tab2){ref-type="table"}). The majority of patients were in the lowest risk category (62.4%). The remaining patients were split between the middle risk categories.Table 2Risk distribution of local population compared to study population by stratification modelModelSmoking HistoryRisk LevelRisk DescriptionStudy PopulationModel PopulationAng et al. 2010 \[[@CR10]\]HPV -ve: 73%\
HPV +ve: 65%Low Risk≦ 10 PYHx\
or\
\> 10 PYHx with N0-N2a66.7%64.0%Intermediate Risk\> 10 PYHx with N2b-N333.3%36.0%O'Sullivan et al. 2013 \[[@CR13]\]HPV -ve: 94%\
HPV +ve: 64%Low riskT1-T3, N0-N2c87.2%74.9%High riskT4,N0-N2c\
or\
N312.8%25.1%Huang et al. 2015 \[[@CR12]\]HPV -ve:\
15 PYHx\
HPV +ve:\
40 PYHxLow Risk≦ 20 PYHx62.4%49.4%Intermediate Risk\> 20 PYHx\
or\
Age ≦ 7037.6%45.9%High RiskAge \> 700.0%4.7%Dahlstrom et al. 2016 \[[@CR11]\]HPV +ve: 82.5%Low RiskT1, N0-N224.8%29.5%Intermediate RiskT2, N0-N2\
or\
T3\
or\
N364.1%59.0%High RiskT411.1%11.5%HPV + ve = p16 positive oropharyngeal squamous cell carcinoma, −ve = negative, PYHx = Pack Year History

Using O'Sullivan et al.'s model, the local patient population was low risk 87.2% of the time (Table [2](#Tab2){ref-type="table"}). This was primarily driven by small primary tumor size. Dahlstrom et al. utilized a similar model \[[@CR11]\], and the local patient population was most commonly in an intermediate risk category (Table [2](#Tab2){ref-type="table"}, 64.1%). Twenty-nine patients (Table [2](#Tab2){ref-type="table"}, 24.8%) were low risk.

Discussion {#Sec9}
==========

This study investigated the p16 + OSCC risk distribution in Nova Scotia using multiple described risk stratification models. Specifics of Nova Scotian p16 + OSCC risk distribution are lacking and this was the first study to address these knowledge gaps in a patient population hypothesized to be high risk due to the high prevalence of tobacco exposure in the provincial population. To our knowledge, this is the first study to directly compare multiple risk stratification models in a local study population.

The prevalence of smoking in Nova Scotia is amongst the highest in Canada, behind only the Territories \[[@CR17]\]. In this study, p16 + OSCC patients in Nova Scotia were found to have substantially increased smoking prevalence compared to both the provincial and national averages. This was especially true of the female p16 + OSCC population, which showed a smoking prevalence double the Nova Scotia age-adjusted population average (60% vs 30%) \[[@CR18]\]. The overall local study population smoking prevalence was similar to the prevalence found in the risk stratification model populations, which ranged from 49 to 72% \[[@CR10], [@CR11], [@CR13]\]. Similarly, the average pack-year history of smokers was non-significantly increased in this study compared to the Canadian average (28.8 vs 25.1 pack-years, *p* \> 0.05) \[[@CR19]\]. This quantity of tobacco exposure was similar to that seen in the validation cohorts of the previously published stratification models in which the average pack-year history was between 12.2 to 38 pack years \[[@CR10]--[@CR12]\].

Despite the high prevalence and quantity of concurrent tobacco exposure, the study population had a similar risk distribution compared to populations in published stratification models. Our study revealed a slightly decreased local population risk compared to the original study by Ang and colleagues \[[@CR10]\]. Nova Scotia patients had a higher likelihood of a ten pack-year history (53.0% vs 50.6%). Despite this, the overall proportion of low risk patients was high (66.7 vs 66.4%). This is most likely due to a smaller proportion of ten pack-year patients having advanced nodal stage (N2b or greater; 62.9% vs 71.1%). The mean age was higher by about five years in our local population.

The model proposed by O'Sullivan and colleagues \[[@CR13]\] yielded the greatest difference in stratification of all models examined. Nodal status was more favourable in the local study population compared to the population studied by O'Sullivan in which 69% of patients had N2b or greater at presentation. Similarly, comparatively few patients presented with T3 to T4 primary tumor in our study population (28% vs 44%). However, the age was similar (58.1 vs 57.0). The large percentage of local patients stratified as low risk by O'Sullivan et al.'s model may be an important consideration in model choice.

With the exception of N3, the distribution of nodal stage was similar between our local population and the population examined by Dahlstrom and colleagues. A similar trend held true for tumor staging. Gender and age were also highly similar. Therefore, the risk distribution patterns of our local population are in keeping with the patterns in the model population.

The mean age of our p16 + OSCC patients was similar to Huang's (58.1 vs 57.8), as was the proportion of T1 -- T3, N0 -- N2c patients with a pack-year history greater than 20 pack-years \[[@CR12]\]. Both the study population and the model are Canadian, and therefore it is expected the age and smoking history would be similar. The group considered to be of highest risk were those patients over the age of 70 with either a T4 or N3 tumor, of which our study identified no patients. In fact, the majority of discrepancy between the populations can be accounted for by the low prevalence of T4 or N3 tumors in our population. Patients with either T4 or N3 were twice as common in the model study population. Interestingly, both Huang et al. \[[@CR12]\] and O'Sullivan et al. \[[@CR13]\] examined populations in Ontario, Canada, and the cancer characteristics were more advanced in those populations. Additionally, the two largest single risk category differences occur in both of these models. It cannot be determined at this time if this is a result of geographical or institutional difference.

The strengths of this study are numerous. It is the first study to directly compare a local study population to multiple putative risk stratification models, two of which were created with similar geographical and jurisdictional populations. The local study population utilized a time period that encompasses the majority of time in which p16 immunohistochemistry was reliably completed at our institution. Multiple databases for identification of potential patients were utilized.

There were several limitations to this study. Despite representing a large portion of cases in our geographical area, the sample size was relatively small. Two databases were used in order to maximize the number of patients included in the study, including the provincial Cancer Care registry and an institutional transoral laser microsurgery database. Despite this consideration, it is impossible to determine if any cases were missed.

This study was not designed as an external validation of the compared risk stratification models, nor do our findings allow for determination if any of the examined models are applicable for determination of mortality in our local population. Revisiting the local patient population and validating the examined models with mortality data would be reasonable in the future.

In summary, this study examined the risk stratification distribution of the p16 + OSCC population in Nova Scotia. This was the first study to compare a local study population to multiple putative risk stratification models. This study also allowed for important demographic information to be gleaned about our local p16 + OSCC population, including smoking history, age, and sex distribution.

The majority of patients were found to be low risk by several putative risk stratification models. The hypothesis that the Nova Scotian p16 + OSCC population would have a lower proportion of low-risk patients was challenged. In concordance with the high rate of tobacco exposure in the Nova Scotia on the whole, the local p16 + OSCC population had a higher prevalence and quantity of tobacco exposure when compared to the populations from other jurisdictions used to validate the available risk stratification models.
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